Tiotropium mist inhaler for COPD increases risk of mortality compared with placebo

Evidence-Based Medicine

Volumn 16, Issue 6, 2011, Pages 189-190

  Ram, Felix S F ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

SALMETEROL; TIOTROPIUM BROMIDE;

CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCHRANE LIBRARY; DRUG FORMULATION; DRUG SAFETY; HUMAN; MORTALITY; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC);

EID: 81855185312     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm.2011.100171     Document Type: Note

References (7)

1. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010;5:197-208.
2. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med 2008;102:32-41.
3. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
4. van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9.
5. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9. (Pubitemid 34864422)
6. Ram FS, Carvallho CR, White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis 2011;6:129-39.
7. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010;363:1097-9.